ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Rhea-AI Summary
Telix (ASX:TLX, NASDAQ:TLX) reported Part 1 results from the global Phase 3 ProstACT trial of TLX591-Tx in post-ARPI metastatic castration-resistant prostate cancer, presented as a late-breaking oral at ASCO 2026.
Across 36 patients given TLX591-Tx plus standard of care, safety and tolerability were acceptable with no new safety signals. Radiation doses to key organs were below established limits, pharmacokinetics showed sustained tumor activity at Day 15, and Part 2 randomized expansion is underway where approved, with FDA engagement ongoing.
AI-generated analysis. Not financial advice.
Positive
- Acceptable safety and tolerability of TLX591-Tx plus SoC in 36 mCRPC patients
- No new safety signals identified across all three treatment cohorts
- All 36 patients received both planned TLX591-Tx doses per protocol
- Radiation exposure to liver, kidneys and salivary glands below established safety limits
- Imaging and pharmacokinetics showed sustained tumor retention and activity through Day 15
- Part 2 randomized expansion initiated in jurisdictions with regulatory approval and FDA discussions underway
Negative
- Grade 4 thrombocytopenia reported in 31% of treated patients
- Grade 4 neutropenia reported in 25% of treated patients
- Grade 3 thrombocytopenia in 14% and Grade 3 neutropenia in 22% of patients
Key Figures
Market Reality Check
Peers on Argus
TLX slipped 1.05% while biotech peers were mixed: RARE -3.87%, ZLAB -2.9%, MLTX -1.05%, APLS -0.05%, LGND +0.48%. Momentum scanner only flagged XENE at +4.67%, suggesting this update was more stock-specific than part of a broad sector rotation.
Previous Clinical trial Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 21 | ASCO selection | Positive | +1.2% | ProstACT Part 1 late-breaking oral selection at ASCO 2026. |
| Apr 14 | Phase 3 initiation | Positive | -0.4% | First patient dosed in Phase 3 IPAX BrIGHT glioblastoma trial. |
| Mar 09 | Part 1 objectives met | Positive | +5.5% | ProstACT Part 1 met safety and dosimetry objectives for TLX591-Tx. |
| Jan 16 | BiPASS first U.S. patient | Positive | +4.4% | First U.S. patient dosed in BiPASS Phase 3 prostate diagnosis study. |
| Dec 21 | Portfolio update | Positive | +3.2% | Precision medicine portfolio update across multiple PET imaging programs. |
Clinical trial updates have typically produced modestly positive moves, with 4 aligned reactions and 1 divergence in the past five tagged events.
Over the past six months, Telix has reported multiple clinical milestones. For ProstACT Global, Part 1 achieved its primary safety and dosimetry objectives and was later selected for a late-breaking oral at ASCO 2026, culminating in today’s detailed Part 1 dataset. In parallel, Telix advanced other Phase 3 programs such as IPAX BrIGHT in glioblastoma and BiPASS in prostate cancer imaging, while also progressing its precision medicine PET portfolio with positive Phase 3 and regulatory updates.
Historical Comparison
In the last five clinical-trial updates, TLX moved an average of 2.78%. Today’s detailed ProstACT Part 1 data extend a pattern where trial milestones often generate modest but generally positive reactions.
Clinical news shows steady progression: ProstACT Part 1 achieved objectives, was elevated to a late-breaking ASCO presentation, and now has full safety, dosimetry and pharmacokinetic data, alongside launches of other Phase 3 programs like IPAX BrIGHT and BiPASS.
Market Pulse Summary
This announcement details Part 1 results from the ProstACT Global Phase 3 trial, showing acceptable safety, tolerability and organ dosimetry for TLX591-Tx combined with standard-of-care therapies in mCRPC, based on 36 patients. It builds on prior disclosures that Part 1 met its primary objectives and advanced to Part 2. Observers may watch for future efficacy readouts, regulatory interactions, and how this therapy complements Telix’s other Phase 3 programs and commercial portfolio.
Key Terms
lutetium-177 medical
radio antibody-drug conjugate medical
metastatic castration-resistant prostate cancer medical
standard of care medical
SPECT/CT medical
dosimetry medical
pharmacokinetics medical
investigational new drug regulatory
AI-generated analysis. Not financial advice.
- Telix’s first-in-class lutetium radio antibody-drug conjugate (rADC) candidate, TLX591-Tx, demonstrates acceptable tolerability across all standard-of-care (SoC) combination cohorts, with no new safety signals.
- Findings support feasibility of TLX591-Tx in combination with contemporary SoC in post-ARPI metastatic castration-resistant prostate cancer (mCRPC).
- Part 2 (randomized treatment expansion) is actively dosing patients in jurisdictions where health authority approval has been granted1.
MELBOURNE, Australia and INDIANAPOLIS, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") announces the oral presentation of Part 1 safety, dosimetry and pharmacokinetics data from the ProstACT Global Phase 3 Study of TLX591-Tx (lutetium-177 (177Lu) rosopatamab tetraxetan), in metastatic castration-resistant prostate cancer (mCRPC). The late-breaking data were presented today at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois by study Principal Investigator Pedro C. Barata, MD, Medical Oncologist, University Hospitals Seidman Cancer Center and Associate Professor of Medicine, Case Western Reserve University of School of Medicine, Cleveland, Ohio.
Results demonstrated that TLX591-Tx, Telix’s lead prostate-specific membrane antigen (PSMA) targeted lutetium rADC therapy candidate, has an acceptable safety and tolerability profile when administered with standard of care (SoC) therapies in mCRPC, with no new safety signals observed.
ProstACT Global is an international, multi-center, randomized Phase 3 trial comparing TLX591-Tx, administered as two doses, 14 days apart with SoC (abiraterone, enzalutamide or docetaxel) versus SoC alone. The study is designed to reflect real-world clinical practice2 and enrolls PSMA-positive mCRPC patients previously treated with one androgen receptor pathway inhibitor (ARPI).
Patients were monitored for treatment-emergent adverse events and underwent serial SPECT/CT3 imaging after TLX591-Tx administration for dosimetry and blood sampling for pharmacokinetics. The primary endpoint was safety and tolerability of TLX591-Tx + SoC. Key secondary endpoints were pharmacokinetics and radiation dosimetry.
Results: Data from 36 patients (baseline median PSA4: 18.18 ng/mL) who received any study treatment were included: Cohort 1 (11 patients), TLX591-Tx + abiraterone; Cohort 2 (11 patients), TLX591-Tx + enzalutamide; Cohort 3 (14 patients), TLX591-Tx followed by docetaxel.
Safety and tolerability
- Acceptable safety profile observed across all combination cohorts, tolerability of TLX591-Tx consistent with prior studies.
- All 36 patients received both doses of TLX591-Tx per protocol.
- No new safety signals identified.
- Almost all treatment-emergent non-hematologic events were Grade 1–2, primarily fatigue (
53% ), nausea (28% ) and dry mouth (25% ). - Hematologic events were transient and manageable: Grade 3 thrombocytopenia (
14% ) and neutropenia (22% ), and Grade 4 thrombocytopenia (31% ) and neutropenia (25% ) events were in line with the profile expected for this class of therapy and extent of disease.
Dosimetry and pharmacokinetics
- Radiation exposure to key organs was well below established safety limits5.
- Highest absorbed dose observed in liver (range, 1.62-5.08 mGy/MBq), with lower doses received by kidneys (0.336-0.961 mGy/MBq) and salivary glands (0.001-0.104 mGy/MBq).
- Lesion dosimetry confirmed uptake across tumor sites and across all cohorts.
- Pharmacokinetics demonstrated sustained activity at Day 15, corroborated by imaging which demonstrated prolonged tumor retention.
- No evidence of drug-drug interactions impacting TLX591-Tx targeting, distribution or clearance.
Telix has initiated Part 2, a 2:1 randomized treatment expansion, in jurisdictions where regulatory approvals have been obtained. Engagement is underway with the United States (U.S.) Food and Drug Administration (FDA) to discuss Part 1 data and seek an Investigational New Drug (IND) amendment to progress Part 2 in the U.S.
Pedro C. Barata, MD, stated, "These results support the feasibility of administering TLX591-Tx alongside current standard-of-care therapies for mCRPC, including ARPIs. Imaging demonstrated sustained tumor retention through day 15, while dosimetry analyses showed radiation exposure below established safety thresholds and limited dose to key organs. Hematologic adverse events were generally consistent with those expected in this patient population and therapeutic class and were transient in most cases. Overall, the safety, dosimetry, and tumor-targeting findings, together with the high treatment compliance observed in this study, support further evaluation of this approach, in the randomized phase of the trial."
David N. Cade, MD, Group Chief Medical Officer, Telix added, "Despite meaningful advances in clinical practice, mCRPC remains a disease where patients urgently need additional first and second-line options. These Part 1 results, presented today at ASCO, build on prior clinical findings and further support our view that TLX591-Tx in combination with contemporary standard of care has the potential to become a new treatment option for this aggressive disease."
The ASCO presentation abstract can be found here.
About ProstACT Global
ProstACT Global (ClinicalTrials.gov ID: NCT06520345) is an international, multicenter trial in two parts: Part 1, safety and dosimetry lead-in with 36 patients (complete); and Part 2, 2:1 randomized global expansion with an overall target enrollment of approximately 490 patients. Eligible patients must have confirmed progressive mCRPC assessed with a 68Ga-PSMA-11 PET6 imaging agent (such as Illuccix®, kit for the preparation of gallium-68 (68Ga) gozetotide injection, or Gozellix®, kit for the preparation of gallium-68 (68Ga) gozetotide injection) following prior treatment with one ARPI.
The antibody approach demonstrates different targeting and pharmacology to that observed in other PSMA-targeted small molecule radioligand therapies (RLT). In contrast to these therapies7, collective long-term follow-up of patients administered with TLX591-Tx has not observed significant acute or delayed kidney toxicity, as the agent is primarily cleared through the liver, a comparatively radioresistant organ, instead of the kidneys8. Due to its large molecular weight, TLX591-Tx also demonstrates minimal salivary and lacrimal gland uptake, reducing dry mouth and dry eyes, common adverse effects of existing PSMA-targeted RLTs9.
Additional information on the Phase 3 ProstACT Global study can be found at: https://telixpharma.com/prostact/
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Telix’s Precision Medicine franchise includes llluccix®, approved in multiple markets globally, and Gozellix®, approved by the U.S. FDA10. TLX591-Tx has not received a marketing authorization in any jurisdiction.
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com | Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com |
Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
____________________________________
1 Part 2 is enrolling in Australia, New Zealand, Canada, Türkiye, and the United Kingdom, and has also received regulatory approval to commence in China, Singapore and South Korea.
2 National Comprehensive Cancer Network® Clinical Practice Guidelines in Oncology for Prostate Cancer V3.2026; Narayan et al. Clin Genitourin Cancer. 2024.
3 Single-photon emission computed tomography.
4 Prostate-specific antigen.
5 Wahl et al. J Nucl Med. 2021; Emami et al. Int J Radiat Oncol Biol Phys. 1991.
6 Positron emission tomography.
7 Tagawa et al. Curr Oncol Rep. 2021; Steinhelfer et al. J Nucl Med. 2024.
8 Tagawa et al. Cancer. 2019.
9 Pepin et al. Pract Radiat Oncol. 2025.
10 Telix ASX disclosure March 21, 2025.
